Lakefront Biotherapeutics NV (LKFT)

Market Cap	1.84B -16.2%
Revenue (ttm)	1.20B +262.2%
Net Income	563.56M
EPS	8.55
Shares Out	65.90M
PE Ratio	3.26
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,205
Open	28.19
Previous Close	28.12
Day's Range	27.78 - 28.37
52-Week Range	26.42 - 37.78
Beta	0.12
Analysts	Hold
Price Target	25.33 (-9.02%)
Earnings Date	Aug 10, 2026

About LKFT

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 452
• Stock Exchange: NASDAQ
• Ticker Symbol: LKFT
• Website: https://lakefrontbio.com

Financial Performance

In 2025, LKFT's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR

Analyst Summary

According to 5 analysts, the average rating for LKFT stock is "Hold." The 12-month stock price target is $25.33, which is a decrease of -9.02% from the latest price.

Price Target

$25.33

(-9.02% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 25, 2026

Data Sources Report a data error